United States
S. 2658
Medication Affordability and Patent Integrity Act
The bill would require pharmaceutical companies to submit certain information and communications to federal health and patent agencies when seeking approval for new drugs or maintaining approval for existing medications. This aims to increase transparency and potentially help the government better understand patent-related issues that may affect drug affordability.[AI-Generated]
Reported by committee 28 July 2026
Record as of 28 July 2026 — the most recent action in the official record. Status can lag; each step below carries its own date.
- 28 July 2026 Reported by committee
What's next: Floor scheduling (leadership decides if and when it gets a vote)
- 28 July 2026 Placed on calendar (Senate)
2 more actions
- 17 June 2026 Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- 19 March 2026 Committee on Health, Education, Labor, and Pensions. Hearings held.
- 1 August 2025 Referred to committee
- 1 August 2025 Introduced in Senate
This path starts where the bill does — its first action in the official record. Routine procedural steps sit in the “more actions” rows above rather than on the main line.
Read the live feed — on the site or in the app Look up S. 2658 on Congress.gov All US bills